Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Common and minor ailment services

London to end minor ailments service with replacement solely for 'vulnerable' patients

Exclusive: A 14-borough London minor ailments service is to end as community pharmacists and health representatives discuss who will be able to access the planned replacement scheme. 

Hitesh Patel photograph

Source: Courtesy of Hitesh Patel

Hitesh Patel, chief officer at the City and Hackney Local Pharmaceutical Committee, said that plans for a replacement service are “at a very early stage”

A community pharmacy-run minor ailments scheme (MAS) exclusively for people who are “socially vulnerable” is being planned for London.

Community pharmacists in the City and Hackney Local Pharmaceutical Committee (LPC) area in east London are expected to trial the scheme — which is still being designed — before it is offered as a model for others to adopt across the capital.

Proposals for the new service have emerged just two months before NHS England London funding for a 14-borough-wide traditional MAS — which includes City and Hackney LPC — is due to run out.

Community pharmacists are due to be sent notices about the service, which ends in late March 2019, in the near future.

How the new MAS would run, how patients’ eligibility would be confirmed and how the service would be funded are still being decided by a working group made up of community pharmacists and representatives from the local clinical commissioning groups (CCGs), public health services and NHS England.

The definition of “social vulnerability” is also being determined by the working group, which is due to meet again before the end of March 2019.

Hitesh Patel, City and Hackney LPC chief officer, told The Pharmaceutical Journal: “We are working with our CCG and NHS London to develop a new service, but it’s at a very early stage.”

NHS England London had originally planned to end the 14-borough MAS service in the summer of 2018, on the grounds that it was not a London-wide service and was therefore “inequitable”. It also claimed that its service specifications were “not fit for purpose” and that some patients were reportedly using the MAS to obtain regular supplies of paracetamol and ibuprofen, rather than when they had an acute need. NHS England London also said it was confident that pharmacists working in GP surgeries could take on some of the MAS work and could direct patients to community pharmacists for self-management of care.

However, community pharmacists won a last-minute reprieve and funding was promised for that MAS until the end of the 2018/2019 financial year. The change of heart was prompted by concerns about the impact the closure would have, particularly on vulnerable patients.

Announcing the delay in June 2018, NHS England London also promised talks to see if there was a way to produce a MAS only for vulnerable patients. 

Developing a MAS exclusively for vulnerable patients follows the closure of other such schemes across England, despite community pharmacists warning that vulnerable patients denied access to free over-the-counter products were being forced to choose whether to “eat or treat”.

Meanwhile, more than 2,000 community pharmacies have now registered to be part of the Digital Minor Illness Referral Service (DMIRS) pilot scheme, where patients who call NHS 111 are given the option of a referral to a named community pharmacist for a booked consultation.

In November 2018, pharmacies from London, Devon and the East Midlands signed up to the pilot run by NHS England. The DMIRS scheme was first launched in the north-east of England in December 2017.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20205996

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.